Wang Huijuan, Wei Yujie, Wang Na
Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.
Purinergic Signal. 2024 Mar 6. doi: 10.1007/s11302-024-09997-8.
Despite the use of various therapies such as hematopoietic stem cell transplantation and chimeric antigen receptor T cell therapy (CAR-T), the prognosis of patients with acute myeloid leukemia (AML) is still generally poor. However, immunotherapy is currently a hot topic in the treatment of hematological tumors. Extracellular adenosine triphosphate (ATP) can be converted to adenosine diphosphate (ADP) via CD39, and ADP can be converted to adenosine via CD73, which can bind to P1 and P2 receptors to exert immunomodulatory effects. Research on the mechanism of the purinergic signaling pathway can provide a new direction for the treatment of AML, and inhibitors of this signaling pathway have been discovered by several researchers and gradually applied in the clinic. In this paper, the mechanism of the purinergic signaling pathway and its clinical application are described, revealing a new target for the treatment of AML and subsequent improvement in patient prognosis.
尽管使用了各种疗法，如造血干细胞移植和嵌合抗原受体T细胞疗法（CAR-T），急性髓系白血病（AML）患者的预后总体上仍然较差。然而，免疫疗法目前是血液肿瘤治疗中的一个热门话题。细胞外三磷酸腺苷（ATP）可通过CD39转化为二磷酸腺苷（ADP），ADP可通过CD73转化为腺苷，腺苷可与P1和P2受体结合发挥免疫调节作用。对嘌呤能信号通路机制的研究可为AML的治疗提供新方向，该信号通路的抑制剂已被多位研究者发现并逐渐应用于临床。本文描述了嘌呤能信号通路的机制及其临床应用，揭示了AML治疗的新靶点以及随后患者预后的改善。
